A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

An Evaluation of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00579020

Enrollment

144

Registered

2007-12-21

Start date

2007-12-31

Completion date

2009-02-28

Last updated

2012-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Infiltrates

Keywords

cornea, inflammation, blepharitis, lid infection

Brief summary

The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.

Interventions

DRUGMoxifloxacin/dexamethasone phosphate ophthalmic solution

DRUGMoxifloxacin ophthalmic solution 0.5%

DRUGDexamethasone phosphate solution, 0.1%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of marginal corneal infiltrates of size equal to or less than 1.5mm in diameter, with mild, moderate or severe bulbar conjunctival injection in at least one eye. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Age related. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Percentage of patients with resolution of all corneal stromal infiltrate(s) in study eye at Test of Cure (TOC) Visit (Day 10)	Day 10

Secondary

Measure	Time frame
Percentage of patients with eradication of pre-therapy pathogens from the lid of the study eye at TOC Visit (Day 10)	Day 10

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026